BG
SAGE

Bellevue Group’s Sage Therapeutics SAGE Stock Holding History

Bellevue Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,460,693
Closed -$24.2M – 164
2024
Q4 		$24.2M Hold
4,460,693
– – 0.47% 52
2024
Q3 		$32.2M Sell
4,460,693
-4,000
-0.1% -$36.6K 0.52% 59
2024
Q2 		$48.5M Sell
4,464,693
-851
-0% -$10.9K 0.79% 31
2024
Q1 		$83.7M Buy
4,465,544
+952,193
+27% +$22M 1.28% 22
2023
Q4 		$76.1M Hold
3,513,351
– – 1.16% 25
2023
Q3 		$72.3M Buy
3,513,351
+398,976
+13% +$11.5M 1.16% 24
2023
Q2 		$146M Buy
3,114,375
+24,375
+0.8% +$1.21M 2.09% 11
2023
Q1 		$130M Buy
3,090,000
+120,722
+4% +$5.19M 1.88% 13
2022
Q4 		$113M Sell
2,969,278
-1,400
-0% -$53.5K 1.5% 19
2022
Q3 		$116M Sell
2,970,678
-2,500
-0.1% -$96.6K 1.67% 14
2022
Q2 		$96M Sell
2,973,178
-79,226
-3% -$2.66M 1.36% 17
2022
Q1 		$101M Sell
3,052,404
-175,600
-5% -$6.6M 1.17% 28
2021
Q4 		$137M Buy
3,228,004
+19,000
+0.6% +$796K 1.42% 20
2021
Q3 		$142M Buy
3,209,004
+844,800
+36% +$38.7M 1.44% 17
2021
Q2 		$134M Buy
2,364,204
+553,500
+31% +$39.1M 1.31% 20
2021
Q1 		$136M Buy
1,810,704
+243,200
+16% +$19.9M 1.43% 18
2020
Q4 		$136M Sell
1,567,504
-12,000
-0.8% -$884K 1.55% 17
2020
Q3 		$96.5M Buy
1,579,504
+164,000
+12% +$8.31M 1.33% 20
2020
Q2 		$58.9M Sell
1,415,504
-2,600
-0.2% -$94.4K 0.83% 33
2020
Q1 		$40.7M Buy
1,418,104
+109,250
+8% +$6.33M 0.79% 36
2019
Q4 		$94.5M Buy
1,308,854
+5,350
+0.4% +$658K 1.5% 19
2019
Q3 		$183M Sell
1,303,504
-17,900
-1% -$2.99M 3.4% 5
2019
Q2 		$242M Buy
1,321,404
+1,305,104
+8,007% +$223M 4.13% 5
2019
Q1 		$2.59M Buy
16,300
+5,700
+54% +$825K 0.14% 99
2018
Q4 		$1.01M Sell
10,600
-600
-5% -$68.7K 0.07% 115
2018
Q3 		$1.58M Sell
11,200
-900
-7% -$139K 0.1% 110
2018
Q2 		$1.89M Sell
12,100
-350
-3% -$54.9K 0.16% 91
2018
Q1 		$2M Sell
12,450
-200
-2% -$34K 0.2% 79
2017
Q4 		$2.08M Buy
+12,650
New +$1.23M 0.22% 76

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Bellevue Group's SAGE Position: Q1 2025 in Review

Bellevue Group sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 4,460,693 shares — an estimated $24.2M sold.

Bellevue Group first reported a position in SAGE in Q4 2017 and held it in 29 quarters. The position peaked at $242M in Q2 2019. 197 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Bellevue Group reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bellevue Group sold 4,460,693 Sage Therapeutics shares in Q1 2025, an estimated $24.2M.
  • Bellevue Group first reported a position in Sage Therapeutics in Q4 2017 and held it in 29 quarters.
  • Bellevue Group's Sage Therapeutics position peaked at $242M in Q2 2019.
  • 197 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.